PCM
XENE icon

PenderFund Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

PenderFund Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$398K Hold
6,850
– – 0.06% 92
2025
Q4 		$307K Hold
6,850
– – 0.05% 92
2025
Q3 		$275K Buy
+6,850
New +$241K 0.05% 87

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PenderFund Capital Management's XENE Position: Q1 2026 in Review

PenderFund Capital Management held its Xenon Pharmaceuticals (XENE) position steady in Q1 2026 at 6,850 shares worth $398K. The position accounts for 0.06% of the portfolio, ranked #92.

PenderFund Capital Management first reported a position in XENE in Q3 2025 and has held it in 3 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • PenderFund Capital Management held 6,850 shares of Xenon Pharmaceuticals worth $398K as of Q1 2026.
  • PenderFund Capital Management left its Xenon Pharmaceuticals share count unchanged in Q1 2026.
  • Xenon Pharmaceuticals made up 0.06% of PenderFund Capital Management's portfolio in Q1 2026, its #92 holding.
  • PenderFund Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on PenderFund Capital Management's 13F filing for Q1 2026, filed 15 May 2026.